Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 26 ... first vaccines focus on infectious diseases, including seasonal and pandemic flu, malaria, dengue, human papillomavirus and respiratory syncytial virus. In 2008 and 2009, ... acquires the use of 3M's patented toll-like receptor (TLR) agonists for use as vaccine adjuvants. Data suggest that 3M's TLR agonists could enhance vaccine potency, ...
2009 NOV 29 ... In a novel approach at disseminating scientific research, the Johns Hopkins Malaria Research Institute (JHMRI) will hold a web summit to release the latest breakthroughs in ... malaria because different tactics will work in different scenarios. In some places, a vaccine may work best, in more remote places, other low cost, low tech approaches will work ...
2009 NOV 1 ... contact E.S. Bergmannleitner, Walter Reed Army Institute Research, US Military Malaria Vaccine Program, Dept. of Molecular Parasitology, 503 Robert Grant Avenue, Silver Spring, MD ...
2009 NOV 9 ... infectious microbes such as food poisoning bacteria, flu viruses and protozoa that cause malaria, one vaccine could be made to prevent a particular disease in all mammals. The research ...
Subject: Biotechnology and Biological Sciences Research Council
2009 NOV 16 ... the Clinton HIV/AIDS Initiative and Rajat Gupta of the Global Fund to Fight HIV, TB, and Malaria. They urge far broader use of the most cost-effective drug regimens for treating ... Although much attention has focused on the scientific obstacles to developing an HIV vaccine, the Massachusetts Institute of Technology's Jeffrey E. Harris contends that the ...
2009 NOV 16 ... outcry." Pneumonia takes the lives of more children under 5 than measles, malaria, and AIDS combined. The disease takes the life of one child every 15 seconds, and ... (pneumococcal disease) and Haemophilus influenzae type b (Hib). However, use of Hib vaccine has only recently expanded to low-income countries and pneumococcal vaccine is not yet ...
Subject: The Global Coalition against Child Pneumonia
2009 NOV 9 ... contact M.S. Silva, IHMT, Unidade Ensino & Invest Clinic Doencas Tropicais, Center Malaria & Outras Doencas Tropicais, Av Junqueira 96, P-1349008 Lisbon, Portugal. ... The researchers concluded: "These results demonstrate that a DNA vaccine coding for trans-sialidase from T. brucei is potentially useful in the prophylaxis of ...
2009 NOV 1 ... important merozoite protein and is currently considered a major candidate antigen for a malaria vaccine. Previously, we showed that AMA-1 has an influence on cellular immune responses of ...
2009 NOV 23 ... that merozoite Surface protein 1 (MSP1) is a target of protective immunity against malaria. In a variety of experimental approaches using in vitro methodology, animal models and ... design and engineer better antigens that are more effective than the first generation of vaccine candidates," wrote A.A. Holder and colleagues. The researchers concluded: ...
2009 NOV 16 ... people in the poorest countries, and collectively cause a health burden comparable to malaria, tuberculosis or AIDS (known as the "Big 3" tropical diseases). The ... United Cell Biotechnology Co. Ltd. (Shanghai, China) manufactures a novel oral cholera vaccine, as does Shantha Biotechnics (Hyderabad, India), whose product provides longer, broader ...
2009 NOV 16 ... function and invasion of hepatocytes. Given its critical nature, a phase III human CSP malaria vaccine trial is ongoing," scientists in the United States report. "The CSP is ...
2009 NOV 1 ... remains a major challenge in the fight against developing country diseases like malaria and AIDS. We describe a novel strategy to identify new DNA vaccine adjuvants." ...
2009 OCT 26 ... According to recent research published in the European Journal of Immunology, "Malaria is a serious cause of morbidity and mortality and yet a vaccine is not available." ...
2009 NOV 16 ... pathogens. Barber and Ishikawa intend to examine STING's effect on parasites, such as malaria, and fungi. They'll also further evaluate the importance of this molecule in ... reacts the same way," says Barber. The theory is that without STING, a DNA-based vaccine wouldn't have the effectiveness because the body would not create interferon and other ...
2009 NOV 1 ... "This brings us one step closer to being able to design a broadly protective malaria vaccine," says Dr. Takala. "Though there are medications that are used to treat malaria, drug ...
2009 NOV 16 ... A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, ...
